Skip to main content

Advertisement

ADVERTISEMENT

Diabetic Macular Edema News

News
03/04/2024

Emry Lloyd

Emry Lloyd
Every year, millions of necessary medical service claims are denied by health care providers; policymakers want to balance these denials for those who need care and how this affects patients with diabetic macular edema.
Every year, millions of necessary medical service claims are denied by health care providers; policymakers want to balance these denials for those who need care and how this affects patients with diabetic macular edema.
Every year, millions of...
03/04/2024
First Report Managed Care
News
01/10/2024
Jolynn Tumolo
Subthreshold micropulse laser therapy was comparable in both efficacy and cost to standard laser therapy in patients with diabetic macular edema (DME) with central retinal thickness less than 400 μm, according to a noninferiority trial...
Subthreshold micropulse laser therapy was comparable in both efficacy and cost to standard laser therapy in patients with diabetic macular edema (DME) with central retinal thickness less than 400 μm, according to a noninferiority trial...
Subthreshold micropulse laser...
01/10/2024
First Report Managed Care
News
11/21/2022
Jolynn Tumolo
To understand whether initial outcomes were a predictor of long-term results, study authors followed patients with diabetic macular edema for several months to assess their responses to anti-vascular endothelial growth factor injections.
To understand whether initial outcomes were a predictor of long-term results, study authors followed patients with diabetic macular edema for several months to assess their responses to anti-vascular endothelial growth factor injections.
To understand whether initial...
11/21/2022
First Report Managed Care

Advertisement

News
11/09/2022
Jolynn Tumolo
“Our results reinforce the importance of a continual reevaluation of the role of intravitreal steroids in diabetic macular edema management,” wrote study authors.
“Our results reinforce the importance of a continual reevaluation of the role of intravitreal steroids in diabetic macular edema management,” wrote study authors.
“Our results reinforce the...
11/09/2022
First Report Managed Care
News
10/24/2022
Jolynn Tumolo
Findings showed targeted therapy improved visual and anatomical outcomes in patients with diabetic macular edema.
Findings showed targeted therapy improved visual and anatomical outcomes in patients with diabetic macular edema.
Findings showed targeted therapy...
10/24/2022
First Report Managed Care
News
10/21/2022
Edan Stanley
Researchers examined the alterations of different aqueous humor cytokine concentrations after intravitreal antivascular endothelial growth factor treatment in patients with diabetic macular edema.
Researchers examined the alterations of different aqueous humor cytokine concentrations after intravitreal antivascular endothelial growth factor treatment in patients with diabetic macular edema.
Researchers examined the...
10/21/2022
First Report Managed Care

Advertisement

News
09/21/2022
Jolynn Tumolo
Intravitreal aflibercept, gender, and other factors "did not interfere with the morphological and functional outcomes of diabetic macular edema in cataract surgery,” researchers said.
Intravitreal aflibercept, gender, and other factors "did not interfere with the morphological and functional outcomes of diabetic macular edema in cataract surgery,” researchers said.
Intravitreal aflibercept,...
09/21/2022
First Report Managed Care
News
09/14/2022
Maria Asimopoulos
Recent findings show the impact of intravitreal aflibercept and ranibizumab on estimated glomerular filtration rates and glycated hemoglobin A1c for patients with diabetic macular edema.
Recent findings show the impact of intravitreal aflibercept and ranibizumab on estimated glomerular filtration rates and glycated hemoglobin A1c for patients with diabetic macular edema.
Recent findings show the impact...
09/14/2022
First Report Managed Care
News
06/02/2022
Jolynn Tumolo
Patients had a lower likelihood of developing diabetic macular edema after receiving preoperative bevacizumab.
Patients had a lower likelihood of developing diabetic macular edema after receiving preoperative bevacizumab.
Patients had a lower likelihood...
06/02/2022
First Report Managed Care

Advertisement

News
02/19/2015
A recent study compared 3 drugs for the treatment of diabetic macular edema—bevacizumab, afilbercept, and ranibizumab—to determine which is the most effective treatment for patients with moderate vision loss.
A recent study compared 3 drugs for the treatment of diabetic macular edema—bevacizumab, afilbercept, and ranibizumab—to determine which is the most effective treatment for patients with moderate vision loss.
A recent study compared 3 drugs...
02/19/2015
First Report Managed Care

Advertisement